LinkedIn stock drops 20 percent on weak earnings

May 2, 2015 at 7:00PM

Not trending: LinkedIn plunged 20 percent Friday after the online-networking service warned of weaker earnings in the months ahead, a result of the stronger dollar and the company's pending purchase of an online learning company. Shares closed at $205.21.

Travel time: Expedia turned in sales results that topped Wall Street's estimates. The online-travel company's stock jumped 8 percent Friday, to $101.69.

Healthy: Merck rose 5 percent, to $59.88 Tuesday when the company's adjusted earnings handily beat analysts' estimates. Shares closed the week at $59.86.

Trolls: Twitter's quarterly results, unexpectedly released before the market closed Tuesday, showed lower than expected revenue, sending its shares down 18 percent, to $42.27. They closed Friday at $37.84.

Pricey wings: Buffalo Wild Wings slumped 12.8 percent, to $159 on Wednesday after the company reported disappointing first-quarter results as the price of chicken wings surged. Shares closed the week at $157.36.

Bad sound: Harman International reported earnings that fell short of analysts' estimates and lowered its own forecast for revenue and earnings. The audio-products company blamed the impact of the appreciating dollar and weaker growth. Its stock fell 5.5 percent Thursday, to $132.83, finishing the week at $126.48.

No results: Yelp plunged 21 percent Thursday, to $40.45 after it reported a loss of $1.3 million in its first quarter and gave a lower-than-expected revenue outlook. Yelp said the number of visitors to its desktop site fell as more users browsed on smartphones and tablets. The stock closed at $39.76 Friday.

ASSOCIATED PRESS

about the writer

about the writer

More from Business

See More
card image
Fairview Health Services

The school is changing an elective course while still working with the Eden Prairie-based health care giant after students raised concerns.

This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in the lab. (NIAID/TNS) ORG XMIT: 1659810
card image